+44 (0)1462 440 084
Who are we?
Coded To Care
Executive Team - David Underwood
Executive Team - Daniel Chapple
Executive Team - Karen Ooms
Executive Team - James Mackellar
Executive Team - Tom Griffith
Executive Team - Amanda Long
Executive Team - Sundar Ramamoorthy
Executive Team - Neil Herron
Clinical Data Management
Regulatory Submission Review
Data Quality Oversight
Clinical Data Visualizations
Pharmacovigilance Safety Database
Clinical Trial Phases
ISS ISE Services
Bayesian Adaptive Designs
Functional Service Provider
IQ - Integrated Quanticate®
Hemophilia Case Study
FSP Model Case Study
Biostatistics & Programming FSP Case Study
Clinical Data Management Case Study
Biosimilar Development Case Study
ISS ISE Case Study
Centralized Statistical Monitoring
Clinical Outsourcing Trends
What is a data-focused CRO?
Statistics Rescue Package
COVID-19 Clinical Trial Support
COVID-19 Webinar: Ensuring Scientific Integrity
Preserving Integrity of Trials During COVID-19
[Free White Paper]
Bayesian Study Design
Using Interim Analyses to Improve Efficiency in Drug Development
This second whitepaper
shows how the Bayesian framework is highly appropriate for planning and executing interim
The rationale for using a Bayesian approach to interim analyses is explained.
The formulation of interim decision rules on the basis of posterior and predictive probability is introduced and evaluated using a case study.
The value of simulations are included to assess the merits of the different decision rules and the relative timing of interim analyses is illustrated.
To receive a copy, please fill out the form.
Download this paper
Phone +44 (0)1462 440 084 | Fax +44 (0)1462 440 086